BRPI0513199A - compostos orgánicos - Google Patents

compostos orgánicos

Info

Publication number
BRPI0513199A
BRPI0513199A BRPI0513199-5A BRPI0513199A BRPI0513199A BR PI0513199 A BRPI0513199 A BR PI0513199A BR PI0513199 A BRPI0513199 A BR PI0513199A BR PI0513199 A BRPI0513199 A BR PI0513199A
Authority
BR
Brazil
Prior art keywords
organic compounds
compounds
medicaments
general formula
preparation
Prior art date
Application number
BRPI0513199-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Peter Herold
Robert Mah
Stefan Stutz
Aleksandar Stojanovic
Vicenzo Tschinke
Nathalie Jotterand
Dirk Behnke
Original Assignee
Speedel Experimenta Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speedel Experimenta Ag filed Critical Speedel Experimenta Ag
Publication of BRPI0513199A publication Critical patent/BRPI0513199A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
BRPI0513199-5A 2004-07-09 2005-07-11 compostos orgánicos BRPI0513199A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH11582004 2004-07-09
PCT/EP2005/053306 WO2006005741A2 (en) 2004-07-09 2005-07-11 Piperdine derivatives as renin inhibitors

Publications (1)

Publication Number Publication Date
BRPI0513199A true BRPI0513199A (pt) 2008-04-29

Family

ID=35448323

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513199-5A BRPI0513199A (pt) 2004-07-09 2005-07-11 compostos orgánicos

Country Status (14)

Country Link
US (1) US20080076766A1 (enExample)
EP (1) EP1776359B1 (enExample)
JP (1) JP4842262B2 (enExample)
CN (1) CN101014594A (enExample)
AR (1) AR053406A1 (enExample)
AT (1) ATE521607T1 (enExample)
BR (1) BRPI0513199A (enExample)
CA (1) CA2570920A1 (enExample)
ES (1) ES2372502T3 (enExample)
IL (1) IL180242A0 (enExample)
PL (1) PL1776359T3 (enExample)
PT (1) PT1776359E (enExample)
TW (1) TW200613274A (enExample)
WO (1) WO2006005741A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE462703T1 (de) 2004-08-25 2010-04-15 Actelion Pharmaceuticals Ltd Bicyclononen-derivate als renin-inhibitoren
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
EP1707202A1 (de) * 2005-03-31 2006-10-04 Speedel Experimenta AG Organische Verbindungen
EP1863763A1 (en) * 2005-03-31 2007-12-12 Speedel Experimenta AG 3,4,5-substituted piperidines as renin inhibitors
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
GB0508992D0 (en) * 2005-05-03 2005-06-08 Novartis Ag Organic compounds
GB0510810D0 (en) * 2005-05-26 2005-06-29 Novartis Ag Organic compounds
BRPI0609890A2 (pt) 2005-05-27 2010-05-04 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
PT2420491E (pt) 2005-12-30 2013-10-14 Novartis Ag Compostos de piperidina 3,5-substituída como inibidores de renina
EP1816122A3 (en) * 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
TW200804359A (en) * 2006-01-19 2008-01-16 Speedel Experimenta Ag Substituted 4-phenylpiperidines
TW200821303A (en) * 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
EP1911758A1 (en) * 2006-10-04 2008-04-16 Speedel Experimenta AG Phenyl piperidine derivatives for use as renin inhibitors
EP1908761A1 (en) * 2006-10-04 2008-04-09 Speedel Experimenta AG Organic compounds
WO2008074450A2 (en) * 2006-12-20 2008-06-26 Nicox S.A. Non-peptidic renin inhibitors nitroderivatives
TWI452044B (zh) * 2007-06-15 2014-09-11 Mitsubishi Tanabe Pharma Corp 嗎啉衍生物
WO2009000811A1 (en) 2007-06-25 2008-12-31 Novartis Ag N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
TW200922596A (en) * 2007-10-25 2009-06-01 Speedel Experimenta Ag 4,4-disubstituted piperidines
TW200932241A (en) * 2007-12-05 2009-08-01 Speedel Experimenta Ag Organic compounds
US8022069B2 (en) 2008-02-08 2011-09-20 Novartis Ag Substituted piperidines as renin inhibitors
MX2010008716A (es) * 2008-02-08 2010-10-25 Novartis Ag Piperidinas sustituidas como inhibidores de renina.
WO2009106599A2 (en) * 2008-02-29 2009-09-03 Novartis Ag Substituted piperidines as therapeutic compounds
WO2009127251A1 (en) * 2008-04-16 2009-10-22 Novartis Ag Combinations comprising a renin inhibitor
CA2722734C (en) * 2008-05-05 2013-11-05 Merck Frosst Canada Ltd. 3,4-substituted piperidine derivatives as renin inhibitors
JP4800445B2 (ja) 2008-06-19 2011-10-26 武田薬品工業株式会社 複素環化合物およびその用途
EP2163245A1 (en) 2008-09-10 2010-03-17 Novartis Ag Renin inhibitors for the treatment of psoriasis
USRE49686E1 (en) 2008-09-19 2023-10-10 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
US20120035214A1 (en) * 2009-04-03 2012-02-09 Merck Canada Inc. Renin inhibitors
EP2384745A3 (en) 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Modified release pharmaceutical compositions of dexlansoprazole
EP2384746A3 (en) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
US8563035B2 (en) 2010-05-05 2013-10-22 Sanovel Ilac Sanayi Ve Ticaret Anomin Sirketi Oral tablet compositions of dexlansoprazole
WO2022117504A1 (en) * 2020-12-02 2022-06-09 Qurient Co., Ltd. Compounds having cyclin-dependent kinase(cdk)-inhibitory function
EP4493551A1 (en) 2022-03-14 2025-01-22 Slap Pharmaceuticals LLC Multicyclic compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100384979B1 (ko) * 1995-09-07 2003-10-17 에프. 호프만-라 로슈 아게 심부전증및신부전증치료용의신규한4-(옥시알콕시페닐)-3-옥시-피페리딘
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6197959B1 (en) * 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
EP1389194A2 (en) * 2001-04-27 2004-02-18 Vertex Pharmaceuticals Incorporated Inhibitors of bace
US20040204455A1 (en) * 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors

Also Published As

Publication number Publication date
WO2006005741A2 (en) 2006-01-19
AR053406A1 (es) 2007-05-09
JP2008505871A (ja) 2008-02-28
CA2570920A1 (en) 2006-01-19
TW200613274A (en) 2006-05-01
WO2006005741A3 (en) 2006-07-06
PL1776359T3 (pl) 2012-01-31
EP1776359B1 (en) 2011-08-24
IL180242A0 (en) 2007-07-04
CN101014594A (zh) 2007-08-08
ATE521607T1 (de) 2011-09-15
EP1776359A2 (en) 2007-04-25
JP4842262B2 (ja) 2011-12-21
US20080076766A1 (en) 2008-03-27
HK1104037A1 (en) 2008-01-04
ES2372502T3 (es) 2012-01-20
PT1776359E (pt) 2011-12-15

Similar Documents

Publication Publication Date Title
BRPI0513199A (pt) compostos orgánicos
BRPI0609719B8 (pt) derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2
BRPI0410760A (pt) compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos
BR122017021516B8 (pt) processo de preparação de uma estrutura de cristal de solvato de (s)-propileno glicol de fórmula ia
UY30438A1 (es) Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos
BRPI0612957B8 (pt) composto, processos de preparação de compostos, composição farmacêutica e uso de um composto
BR122019010008B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BRPI0709633B8 (pt) derivados de piridina e pirimidina como antagonistas de mglur2, composição farmacêutica e uso dos mesmos
BR0316375A (pt) Diazinopirimidinas
NO20070339L (no) 1-aza-bicyklo[3 3.1]nonaner
BRPI0516842A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por lxr alfa e/ou lxr beta agonistas e uso desses compostos
SE0401762D0 (sv) Novel compounds
BRPI0900983B8 (pt) composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso
BRPI0406717A (pt) Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção
BRPI0510849A (pt) compostos inibidores de dpp-iv, sais farmaceuticamente aceitáveis e pró-fármacos dos mesmos, composição farmacêutica compreendendo os mesmo e uso dos referidos compostos na fabricação de medicamento
BRPI0518898A2 (pt) composto, processo para sua preparaÇço, composiÇço farmacÊutica, mÉtodo para tratamento e uso do composto
BRPI0508724A (pt) derivados do fenilaminoetanol como agonistas do receptor beta2
UY27593A1 (es) Nuevos compuestos
BR0317459A (pt) Novos derivados de piperidina como moduladores do receptor ccr5 quimiocina
BRPI0612580A8 (pt) glicinamidas substituídas, processo para a sua preparação e uso da mesma como medicamentos
BRPI0513056A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, método para produzir um efeito anti-proliferativo em um animal de sangue quente
BRPI0909737A2 (pt) compostos de pirrolidinila, composição farmacêutica compreendendo os mesmos e usos dos mesmos
BRPI0508969A (pt) compostos orgánicos
BRPI0519620A2 (pt) compostos, processo para a sua manufatura, composiÇÕes farmacÊuticas que os compreendem, mÉtodo para o tratamento terapÊutico e/ou profilÁtico de enfermidades que sço moduladas por agonistas alfa-lxr e/ou beta-lxr e utilizaÇço desses compostos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.